Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NXHRd5RVTnWwY4Tpc44hSXO|YYm= NVjDS4x7OiEQvF2= M{TvO|EhcA>? M3rQR4lvcGmkaYTzJJRp\SCOLVTPVGEhMDJywrFOwG0qNWmwZIXj[YQhfHKjboPp[Y51KEWUS{GvNkBxcG:|cHjvdplt[XSrb39CpC=> MWeyOlM3OzF7MR?=
C2C12 NE\zOYZHfW6ldHnvckBCe3OjeR?= MY[xxsDPxGdxbXy= NYnxWZVqOcLiaB?= MVnhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz NXmwdodHOjZ{OUGyO|k>
MEFs WT M3q0[GZ2dmO2aX;uJGF{e2G7 M3;LSVXDqM7:TR?= NGDFS4UzOCCvaX6= MYXjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT MVGyOlE6PjB{Mx?=
MEFs VAMP7 KO MlfhSpVv[3Srb36gRZN{[Xl? M2TidFXDqM7:TR?= NF;vd2wzOCCvaX6= MYTjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT M2HkVVI3OTl4MEKz
SMCs NFfoOINHfW6ldHnvckBCe3OjeR?= M1jtNlExyqEEtXevcYw> M3nZO|AuOTJiaB?= M3zJOGROW09? MVTzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NUG5eG1VOjZzN{KwPFA>
SMCs NImw[XFHfW6ldHnvckBCe3OjeR?= NXuwdXU6OTEEoNM1[{9udA>? M{f1e|AuOTJiaB?= MnfaSG1UVw>? M1X5WYNifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? MnzkNlYyPzJyOEC=
HEMC-1 NE\SdGpHfW6ldHnvckBCe3OjeR?= Ml;rNE4yyqEEtXevcYw> NYfnblI2OjUEoHi= NHvUfWJk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> M1jZdFI2QTd{N{W5
HUVEC M3q2NGZ2dmO2aX;uJGF{e2G7 NHL6R2EyOMLizszN M{HON|HDqGh? MXrEUXNQ M3XiToFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W| NVW3R3FqOjV7NU[5PFg>
HUVEC NYroeo1GTnWwY4Tpc44hSXO|YYm= MmTTNVDDqM7:TR?= MlPSNeKhcA>? NGHi[JFFVVOR NIWxZZRqdmO{ZXHz[ZPDqHSqZTDueY1j\XJiYX7kJIlvfGWwc3n0fUBw\iCobIXvdoV{[2WwdDDhdoVieyCnc4DlZ4lidGy7IHnuJJBmemmwdXPs[YFzKHOyYXPl NWTldWJ4OjV7NU[5PFg>
Caco-2 NIjGVIVHfW6ldHnvckBCe3OjeR?= NVj2O|dvOi53IN88US=> NGrZe3Y{OCCvaX6= MkHnZZR1\W63YYTld{B1cGViVFfGMe6zOS2vZXTpZZRm\CCrbnPy[YF{\SCrbjDTSXJVKG[3bnP0bY9v MnrQNlU6PTR7M{G=
NRK M1vlcWZ2dmO2aX;uJGF{e2G7 NWHzVIlJOjBy4pEFcocwdWx? M4XDdFTjiIWq MYPEUXNQ NUWzWWlOemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v NX31[nFnOjV7NEi1PFY>
HeLa NGfFS|hHfW6ldHnvckBCe3OjeR?= NH30[lMzODEkgJXu[{9udA>? Mlu5N{Bp M2jycWROW09? M3HLZYlv\HWlZYOgeIhmKGG{dHnmbYNq[WxiYoLlZYsufXBib3[geIhmKEexbHfpJINwdXCuZYi= NW\mRnNQOjV7NEi1PFY>
COS NHHPRndHfW6ldHnvckBCe3OjeR?= MnjHNUDPxGdxbXy= MYKzJIg> MVXjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> M3vMdlI2QTF3OUCw
DF1  MUPGeY5kfGmxbjDBd5NigQ>? MlzTNeKh|ryPwrC= NViwb3BLPDhiaB?= MkPESG1UVw>? MU\kbZNx\XK|ZYRCpJRp\SCneH;n[Y5wfXNiQ2PHZYxPSWOWMjDwdo91\Wmw M2DOflI2QDB5MEW0
nHDFs  MW\GeY5kfGmxbjDBd5NigQ>? M4P3[|HDqM7:TdMg NVXzXItiOsLiaB?= MoPrdJJmfmWwdIOgeIhmKGG|c3XtZox6KG:oIHP5eI9{d2yrYzDjc4F1KHC{b4TlbY5{KG:wdH:gS49t\2libXXtZpJidmW| MkHTNlU4PzJ4MU[=
FRT  M{\VfmZ2dmO2aX;uJGF{e2G7 MojKOUDPxGdxbXy= MoPsNuKhcA>? M{LGOoJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 NVvUSnY5OjV5NkexNVU>
FRT  MWrGeY5kfGmxbjDBd5NigQ>? MoK3OUDPxGdxbXy= M1HpflLDqGh? M{XRNpBz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDjcIVifmWmIN8xJJN2[nWwaYTzJJdp\W5iW17hL31qyqC5YYOgdoVlfWOnZB?= NILVXpMzPTd4N{GxOS=>
HepG2  M2\Z[GZ2dmO2aX;uJGF{e2G7 MVOx5qCKyrWPwrC= MXeyOEBp NGDDe2lFVVOR MUTk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKFC[UjDtVm5C MX2yOVYyPjV7Nx?=
SMCs NF[2Z3lHfW6ldHnvckBCe3OjeR?= M13YZlHPxGdxbVy= NXewXY5ROyCq MYnhZ4N2dXWuYYTld{BEVlC\MjDwdo91\WmwIHnuJJRp\SCHUjDjc41x[XK2bXXueEBidmRibn:gcI9v\2W{IHPvMYxw[2GuaYrl[EB4cXSqIITo[UBId2ypaTDtZZJs\XMEoB?= NV;nTlQ{OjV3OEm0NlU>
OB-6 M3\BTGFxd3C2b4Ppd{BCe3OjeR?= M3[1fVIvP8LizszN M3yyXFQ5KGh? NVLpbXdDcW6mdXPld{BieG:ydH;zbZM> MlmxNlU2OzJ2OEC=
iPSC-CMs  M2fOWGZ2dmO2aX;uJGF{e2G7 NWLEbGtLPTByIH7nM41t MnvwOFghcA>? NWnaZXdFcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhfGinIHjp[4hmeiCvb3LpcIl1gSCOQV3Qd{BifCC2aHWgZ49{fCCxZjD0bIUhdG:5ZYKgcY9jcWyrdImgd5Bm[2mncx?= NVzaO5VTOjV2OEi2OlY>
SP-Nluc MYLGeY5kfGmxbjDBd5NigQ>? M3HoN|UhdWdxbVy= MXe2JIg> MWfEUXNQyqB? M2O2[YNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> MmHZNlU{QTJ7OUi=
PEXEL-Nluc MknESpVv[3Srb36gRZN{[Xl? MmmzOUBu\y:vTB?= MmO0OkBp MnP4SG1UV8Li NGSwRYNk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NEHPNoozPTN7Mkm5PC=>
H1299 NYLBToo3TnWwY4Tpc44hSXO|YYm= NWPYW3Y4OTBizsznM41t MknxNlQhcA>? MleybY5lfWOnczDheZRweGijZ4pCpC=> M3rx[VI2Ozh6OUew
MDA-MB-231 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV7PUFVCOOLCk{WwJO69\y:vTB?= MnS0OFghcA>? M2q0N2VEPTEEoE2gNE4xOTZiwsXnM41N NWn6VmZxOjV|NU[1Olc>
MDA-MB-231 MWnBdI9xfG:|aYOgRZN{[Xl? NF\nXZMxNjFizsznM41N NVvtUlhIPCCq NW\sdpJzcW6mdXPld{BieG:ydH;zbZM> NGXmdlAzPTN3NkW2Oy=>
MDA-MB-231 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[wUpUxNjBzL{CuNFUh|rypL33M M1TqUlI1KGh? MlHXbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= MVqyOVM2PjV4Nx?=
MDA-MB-231 M2nPXWFxd3C2b4Ppd{BCe3OjeR?= MYmwMlA26oDVMTFOwIcwdUx? NVuxfoRrOjRiaB?= NIf0XplqdmS3Y3XzJHBCWlBiKIDvcJkhSUSSLYLpZo9{\SCyb3z5cYVz[XOnLUGpJINt\WG4YXfl MonsNlU{PTZ3Nke=
MDA-MB-231 NVK2cVY2TnWwY4Tpc44hSXO|YYm= MUew5qCUPTBizsznM41N NETEcoUzPCCq MWTpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= MV[yOVM2PjV4Nx?=
A172 NY\IW4drTnWwY4Tpc44hSXO|YYm= M4nDfVExyqEQvHevcYw> NF;Ib281yqCq MVXEUXNQyqB? M1zNTpJme3WudIOgbY4hfGinIILleJJw\3KjZHWgeJJidnOyb4L0JI9nKG[udX;y[ZNk\W62IHfyZY52dGW| NWqxNnJ5OjV{M{m1NFc>
KMS-6 MVPGeY5kfGmxbjDBd5NigQ>? M3myWVHDqM7:TdMg M1mxOFI1KGh? NE\JVXNmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= NGGxfG8zPTJ{OUGyOi=>
MEC NUHGN4JMTnWwY4Tpc44hSXO|YYm= MoHNNUDPxE1? MX[xMlUhcA>? NFiySlVk[XW|ZYOgZUBlemGvYYTpZ{Bl\WO{ZXHz[UBqdiC2aHWgd5Vz\mGlZTDWSWdHWjJ? MmPZNlUzOjh6MUW=
HEK293/hERG MV7GeY5kfGmxbjDBd5NigQ>? M{L0cVExyqEQvF2= M2jQ[lHDqGh? M3S4V5Jme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi MkfDNlUzOTh2Nkm=
RBE4 MXzBdI9xfG:|aYOgRZN{[Xl? MVeyxsDPxE1? NGjQNXM{6oDVMkVCpIg> NYHzWYJ3cW6mdXPld{BieG:ydH;zbZMhfGmvZTDk[ZBmdmSnboTsfS=> M3THO|I2OTJ6MEK1
RBE4 MmjHSpVv[3Srb36gRZN{[Xl? NXftZVJZOsLizszN M1\ZTFPjiJN{NNMgbC=> NXjwdYd4cW6lcnXhd4V{KHSqZTDYRnAyKHC{b4TlbY4hdGW4ZXzzJIFnfGW{IEOgZY5lKDcEoHigc4YhfHKnYYTt[Y51 MmLZNlUyOjhyMkW=
RBE4 NV\seXg{TnWwY4Tpc44hSXO|YYm= MlPENuKh|ryP M4\UVFPjiJN{NNMgbC=> MWPpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NF;a[2UzPTF{OECyOS=>
RBE4 MXnGeY5kfGmxbjDBd5NigQ>? M4jLb|LDqM7:TR?= NWHPOYdsO+LCk{K0xsBp M{nTXolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLPV{B1cW2nLXTldIVv\GWwdHz5 NVfhWJFWOjVzMkiwNlU>
RBE4 MonGSpVv[3Srb36gRZN{[Xl? NV7sbllYOsLizszN NXT4eY5zO+LCk{K0xsBp NULSV5hucW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 NVLJeFNoOjVzMkiwNlU>
RBE4 NGX3ZmxHfW6ldHnvckBCe3OjeR?= M{CzSFLDqM7:TR?= MXKz5qCUOjUEoHi= MXjpcoR2[2W|IHHuJI93\XKub3HkJI9nKEOjMjxCpIlvKHSqZTDtbZRw[2ixbnTybYEhcW5idHjlJIZqenO2IEdCpIghd2ZiaX7jeYJifGmxbjCodQKBkT{kgJmwMlAxOSliYoX0JGNiOiwEoHzleoVteyCrbjD0bIl{KG:{Z3Hu[Yxt\SCmZXPy[YF{\WRiYX\0[ZIhOTMEoHigc4YhcW6ldXLheIlwdg>? MkDFNlUyOjhyMkW=
Huh-7  M2PKc2Z2dmO2aX;uJGF{e2G7 MW[x{txoN22O MkjQN-KBmzJ2wrDo MonLbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NVHMe5lFOjVyMk[xO|Q>
HepG2  MlnzSpVv[3Srb36gRZN{[Xl? NXjjWpNDOc7:Zz;tUC=> MkTZN-KBmzJ2wrDo M3XmUIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MnXrNlUxOjZzN{S=
H838-LKB1 M2HqbGZ2dmO2aX;uJGF{e2G7 NGWwUIk{OMLibnevcYw> NYDw[WhmOTJxMUigbC=> MlLqbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NWTITIxPOjVyMUGwPFI>
H838-KDLKB1  MWXGeY5kfGmxbjDBd5NigQ>? M3v1dlMxyqCwZz;tcC=> NELs[IEyOi9zODDo MmHkbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> Ml3wNlUxOTFyOEK=
H838-KDLKB1  Mk\USpVv[3Srb36gRZN{[Xl? NXLWe|hbOzEEoH7nM41t NUexdVVnOTJxMUigbC=> MnLwbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= MoLTNlUxOTFyOEK=
3T3-L1 M3rQfmZ2dmO2aX;uJGF{e2G7 NUP2RZlzPSEQvHevcYw> Mn;MN|AhdWmw NF\pboJucW2rY4OgeIhmKGWoZnXjeJMhd2ZiaX7zeYxqdiCjbnSgZ4F2e2W|IILvZpV{fCCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JEhU\XJiNEezLUBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIFHTNVYxKCiWaIKgOlQzKGGwZDDT[ZIhPTh6KR?= MWmyOFg1Ozh{Nx?=
3T3-L1 NXq5ZohwTnWwY4Tpc44hSXO|YYm= M1:yT|Uh|rypL33s NUnLSFJCOzBibXnu NUDmWHg{emWlYYDpeJVt[XSnczDpcpN2dGmwIHHjeIlwdiC5aYToJJJme3CnY4SgeI8hemWpdXzheIlv\yCDa4SgZYN1cX[rdImgZY5lKEGVMU[wJJBpd3OyaH;yfYxifGmxbh?= NHPnSIQzPDh2M{iyOy=>
3T3-L1 MVTGeY5kfGmxbjDBd5NigQ>? NIP3dmk2KM7:Zz;tcC=> NHHVcVI{OCCvaX6= MVLjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? M2XDVVI1QDR|OEK3
3T3-L1 NEL4U2ZHfW6ldHnvckBCe3OjeR?= NHPhW402KM7:Zz;tcC=> MoLwNeKhcA>? MY\jZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> NHGwemYzPDh2M{iyOy=>
3T3-L1 MnrhSpVv[3Srb36gRZN{[Xl? M{nNSFUh|rypL33s NWDxb4lSOcLiaB?= NUfrSWU4[2G3c3XzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3J? M3TBVVI1QDR|OEK3
HeLa  NGX1VYJHfW6ldHnvckBCe3OjeR?= MnTKOUDPxGdxbXy= MlHYN{Bp M1HSfINifXOnczDueYNt\WG{IHX4Z4x2e2mxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3JiYX7kJIRm[3KnYYPld{B1emGwc3PybZB1cW:wIH;mJGZwgE9zLYLl[5Vt[XSnZDDn[Y5mew>? MWGyOFg1Ozh{Nx?=
HEK293 MUTGeY5kfGmxbjDBd5NigQ>? MmTtOeKh|rypL33s MX:xNuKhcA>? MWjhZo9tcXOqZYOgR21CNWmwZIXj[YQhS1KHTFSyJJNm[3KndHnvci=> NX7zXZg{OjR4OEe0N|E>
COS-1 NFLvVpZHfW6ldHnvckBCe3OjeR?= MUK1JOK2\y:vbB?= NIO0WlAzPCCqwrC= Mm\MdoV{fHKrY4TzJIxw[2GuaYrheIlwdiCxZjDORkBqdiC2aHWgdIVzcW63Y3zlZZIhemWpaX;uxsA> M4izWlI1PjdzN{Wx
PRP MYXGeY5kfGmxbjDBd5NigQ>? MWixNEDPxE1? MUDhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? MorxNlQ3Pjh5NUC=
RAW264.7 Mn\yRZBweHSxc3nzJGF{e2G7 MX:0JO69VQ>? NYHKfXJKPDhiaB?= MYrheJRmdnWjdHXzJJRp\SCrbnjpZol1cW:wIH;mJI95NUyGTD3pcoR2[2WmIHHwc5B1d3OrczDhcoQhfGinIH\hZ4ltcXSjdHnvckBw\iClaH;s[ZN1\XKxbDDl[oZtfXhiYomgRYMucEVvMUjBMW5JOg>? MY[yOFY{QTB|Mh?=
MDMs M4\IbGFxd3C2b4Ppd{BCe3OjeR?= MUKxNQKBkc7:Zz;tcC=> M2PscVEzNzF3IHi= MVnpcoR2[2W|IHHwc5B1d3Orcx?= NVfSU3BHOjR3NU[2PVU>
PMHs  NX36NpkxTnWwY4Tpc44hSXO|YYm= M{DXR|Ex6oDVMkFihKnPxGdxbXy= MWWyOQKBkWh? MWLEUXNQ NIjX[|BqdmS3Y3XkJGVTKHO2cnXzdy=> MVyyOFQxPzJ2Mh?=
PMHs  M37CeGFxd3C2b4Ppd{BCe3OjeR?= NHTFdngyOOLCk{Kw5qCK|rypL33s Mn6wNlTjiImq NEjKSJZFVVOR MmfMbY5kemWjc3XzJINmdGxiZHXheIg> M3\reVI1PDB5MkSy
HEK293/tau M2[xT2Z2dmO2aX;uJGF{e2G7 M2DEPVUh|ryP NF2xU3cyNzJxNDDo M1z6Wolv\HWlZYOgS49t\2liZoLh[41mdnSjdHnvcuKh MW[yOFM3QDB6OR?=
HEK293/tau Mk\TSpVv[3Srb36gRZN{[Xl? NGDwUIQ2KM7:TR?= MlTBN{Bp MW\pcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? M4H6NFI1OzZ6MEi5
ADF MUXGeY5kfGmxbjDBd5NigQ>? M3PYbFExKM7:TR?= MkTZNVYhcA>? Mo\RbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MnzpNlQzOjh{M{K=
U373  MoHiSpVv[3Srb36gRZN{[Xl? M2D6WFExKM7:TR?= NUW3bIY{OTZiaB?= NFTDdZdqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? NVfnS2NpOjR{MkiyN|I>
RKO-HIPK2i NUjIPIl{TnWwY4Tpc44hSXO|YYm= MYmxNEDPxE1? Mni0NVYhcA>? MVrpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NW\lVGdROjR{MkiyN|I>
ADF  M4e4d2Z2dmO2aX;uJGF{e2G7 NVT5ZW1EOTBizszNxsA> NVPhRVd6PiCq NGi5OlNqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u MmTsNlQzOjh{M{K=
Huh7 NF\XRXNHfW6ldHnvckBCe3OjeR?= NVnVTI9qPSEQvHevcYw> MUe0JIg> NELxdmhi[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MmLNNlQyODBzNEC=
Huh7 MWnGeY5kfGmxbjDBd5NigQ>? MmjNOUDPxGdxbXy= MVWxJIg> MWHjZZV{\XNiYTDzbYdvcW[rY3HueEBqdmO{ZXHz[UBqdiCDcH;CMYNz\XOlZX70dy=> MkXaNlQyODBzNEC=
Huh7 M3r1VmZ2dmO2aX;uJGF{e2G7 NXTOXGU2PeLCk{GwxsBv\y:vbB?= NWDYeoo{OTJiaB?= MXjpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= MXiyOFExODF2MB?=
BAECs MmnySpVv[3Srb36gRZN{[Xl? M3fTV|Uh|rypL33s MoiyNE01KGh? MV;pcoR2[2W|IITo[UBz[XCrZDDk[ZBpd3OyaH;yfYxifGmxbjDv[kBmVk:VIHH0JHNmejFzN{m= NInzeYUzPDB6NUKyOS=>
Macrophages NWqzZVRKTnWwY4Tpc44hSXO|YYm= M1;De|cyKML3TR?= NGXjZYo3KGh? NWqwbZo{cW6qaXLpeJMhdHWwYYPpckBqdnSncn7hcIl7[XSrb39CpC=> NUXGW203OjRyM{m3OFA>
Colo 205 M{XORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\WTngxNTVizsznM41N MUe0PEBp NUL6UG8{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> Ml\3NlM6PzN7OU[=
Colo 205 NUDIeJVwTnWwY4Tpc44hSXO|YYm= MVuwMlAyOi1yLkCyOUDPxGdxbVy= MnqwNVQh\A>? MVjy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? NVvtUoF4OjN7N{O5PVY>
Colo 205 NVPGW4g4SXCxcITvd4l{KEG|c3H5 M3Xx[|AvOSEQvHevcWw> MXSwMVI1KGh? NYn6OFZZcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= M3zLcVI{QTd|OUm2
Colo 205 M2frT2Z2dmO2aX;uJGF{e2G7 M2KxN|AvODF3IN88[{9uVA>? NFzJPFMzPCCq NEH0VmJqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGVTKHO2cnXzd{1z\WyjdHXkJIdmdmW| NHjXV4IzOzl5M{m5Oi=>
Colo 205 NWDo[Gl6TnWwY4Tpc44hSXO|YYm= NWnvXZhkOC5yMUWg{txoN22O MmPHNlQhcA>? Mmn1bY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> NYSxc3g6OjN7N{O5PVY>
IBRS2 MYXGeY5kfGmxbjDBd5NigQ>? MlryOUDPxGdxbXy= NFm4NIExNjViaB?= Mn3USG1UVw>? NILrO4dlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? MWKyN|k3OzV|NB?=
IBRS2 MUjGeY5kfGmxbjDBd5NigQ>? MnnLOUDPxGdxbXy= MlfLNE42KGh? NVrF[VNrTE2VTx?= Ml30[Y5p[W6lZYOgSm1FXiCrbn\lZ5Rqd25? MoW5NlM6PjN3M{S=
HeLa MUPGeY5kfGmxbjDBd5NigQ>? M3f6SlIh|ryP MlnxNkBpyqB? MVvheJRmdnWjdHXzJJRp\SCWTl[tbY5lfWOnZDDz[YNz\XSrb36gc4YhUUxvMUW= NYfZNHY1OjN7NUC4PVI>
HFS  NUD5NI02TnWwY4Tpc44hSXO|YYm= MUKwMVEh|rypL33s MX[yOEBp NX;tfpRNT0yWUDDlfJBz\XO|aX;uJJJm[WOqZYOgZUBxdGG2ZXH1JIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzINM1[{9udA>? MnLDNlM5QTR4M{O=
HFS  MWLGeY5kfGmxbjDBd5NigQ>? Mny5NE4xOSEEtXevcYw> M1jFRVI1KGh? Mn6wbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? Mof5NlM5QTR4M{O=
OVCAR-3 M4nENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDxNgKBmzF3wrFOwG3DqA>? M3rzW|I1yqCq NIX0UFRqdmS3Y3XzJIEhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7wrC= MnLXNlM5OjZ7NkS=
OVCAR-3 MoPHSpVv[3Srb36gRZN{[Xl? MYqx5qCUOTYEoN88UeKh MUCyOOKhcA>? MYXpcoR2[2W|IH71Z4xm[XJiZHHtZYdm MVeyN|gzPjl4NB?=
OVCAR-3 Mn7xRZBweHSxc3nzJGF{e2G7 NHG2emMyNTFywrFOwG0> M2H1flQhcA>? M1uyTIlv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= M4C3bFI{QDJ4OU[0
OVCAR-3 M3f6NWFxd3C2b4Ppd{BCe3OjeR?= NYqwVGtmOTEEoN88US=> MVGyOOKhcA>? Mk\rbY5lfWOnczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4V{ M3WyOFI{QDJ4OU[0
OVCAR-3 NEHUT3dHfW6ldHnvckBCe3OjeR?= MWGx5qCUOTEEoN88US=> M1jINVI1yqCq NGXnemtqdmS3Y3XzJIRqe3K3cITpc44hd2ZidHjlJI1qfG:laH;u[JJq[WxidILhcpNu\W2kcnHu[UBxd3SnboTpZYw> M{TIWFI{QDJ4OU[0
OVCAR-3 M4\UU2Z2dmO2aX;uJGF{e2G7 M{\vSlHjiJNzMNMg{txO NXjOV3VuOjUEoHi= Ml\PbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= MojuNlM5OjZ7NkS=
OVCAR-3 MoPKSpVv[3Srb36gRZN{[Xl? MWGx5qCUOTEEoN88US=> MknoNlTDqGh? NVLrelJicW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NXnYWnFJOjN6Mk[5OlQ>
MKN45 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2ODxyLkCwNUDPxGdxbXy= Ml;nNlM4QTN|NEK=
LOVO M2DreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjkO2J2UUN3ME2wMlEzKM7:Zz;tcC=> M1n4eVI{Pzl|M{Sy
A549 M2LHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSwXplsUUN3ME2wMlA1KM7:Zz;tcC=> MVGyN|c6OzN2Mh?=
MDA-MB-435 NHT2bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XWPWlEPTB:MD6wNFEh|rypL33s MoTaNlM4QTN|NEK=
HepG2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILxWo9KSzVyPECuNFAyKM7:Zz;tcC=> MWGyN|c6OzN2Mh?=
HL-60 NE\SeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DSWWlEPTB:MD6wNFEh|rypL33s NH63SngzOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID